Keyphrases
Acute Lymphoblastic Leukemia
57%
Pediatric Acute Lymphoblastic Leukemia
51%
Claims Database
48%
Healthcare Utilization
41%
United States
41%
Pediatric
38%
Commercial Insurance
35%
Health Care Costs
33%
Commercially Insured
28%
Insurance Claims Database
28%
Pediatric Patients
27%
Allotransplantation
24%
Age at Diagnosis
24%
State Effects
24%
Chimeric Antigen Receptor T-cell Therapy
24%
Urine Culture
24%
Graft-versus-host Disease (GvHD)
24%
Hematohidrosis
24%
Phase II Study
24%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
24%
Myeloablative
24%
Tacrolimus
24%
Mycophenolate Mofetil
24%
Urine Contamination
24%
Clean Catch Urine
24%
Vancomycin
24%
Fever
24%
Inpatient Rehabilitation
24%
High-dose Cytarabine
24%
Commercial Claims
24%
Sweating
24%
COVID-19 Pandemic Impact
24%
Older Adults
24%
Adult Acute Lymphoblastic Leukemia
24%
Rehabilitation Services
24%
Post-transplantation Cyclophosphamide (PTCy)
24%
Clinical Manifestations
24%
Fanconi Anemia
24%
Systematized Review
24%
COVID-19 Pandemic
19%
Hematopoietic Cell Transplantation
16%
Inpatient Days
15%
Urethral Catheterization
14%
Data Warehouse
13%
Insurance Coverage
13%
Insurance Data
10%
Leukemia Therapy
10%
Outpatient Encounter
10%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Positive Culture
9%
Medicine and Dentistry
Health Care Cost
100%
Acute Lymphoblastic Leukemia
96%
Pediatrics
78%
Outpatient
43%
Pediatrics Patient
24%
Cytarabine
24%
Drug Megadose
24%
Vancomycin
24%
Chimeric Antigen Receptor T-Cell Immunotherapy
24%
Urine Culture
24%
Emotional Stress
24%
Scalp
24%
Stress
24%
Bleeding
24%
Propranolol
24%
Rehabilitation Engineering
24%
Genetic Predisposition
24%
Symptom
24%
COVID-19
24%
Fanconi Anemia
24%
Blood Culture
18%
Chimeric Antigen Receptor
13%
Bacteremia
12%
Infusion
11%
Urethral Catheterization
10%
Childhood Cancer
7%
Hematopoietic Stem Cell
7%
Cell Transplantation
7%
Malignant Neoplasm
7%
Cancer
7%
Leukemia
7%
Diagnosis
6%
Monotherapy
6%
Hematologic Malignancy
6%
Nucleoside Analogue
6%
Chemotherapy Regimens
6%
Cephalosporin
6%
Adverse Event
6%
Antibiotics
6%
Cost Benefit Analysis
5%